Form D · Biotechnology
Vivace Therapeutics, Inc.
San Mateo, CA · CIK 0001630575
Offering snapshot reported Mar 12, 2025 · SEC filing
- Reported sold
- $17.5M Offering amount: $35M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 28, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 12, 2025 | Initial | $17,499,997 | No comparison | 5 | SEC filing |
| Dec 23, 2020 | Initial | $29,999,993 | No comparison | 6 | SEC filing |
| May 1, 2018 | Amendment | $8,000,008 | $0vs May 18, 2017 | 6 | SEC filing |
| May 18, 2017 | Initial | $8,000,008 | No comparison | 6 | SEC filing |
| Jan 20, 2015 | Initial | $5,050,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-540658
Shares of Series D Preferred Stock, and the Common Stock issuable upon conversion thereof.
Source: Form D, filed Mar 12, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sheng Ding | Executive |
| Edward Hu | Director |
| Leonard Post | Director |
| Shuang Qiao | Director, Executive |
| Tim Shannon | Director |
| Jake Simson | Director |
| Jun Wu | Director |
| Chenguang Zhou | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1510 Fashion Island Blvd., Suite 310
San Mateo, CA, 94404
San Mateo, CA, 94404